The Role of Interleukin-18, Oxidative Stress and Metabolic Syndrome in Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The role of interleukins (ILs) and oxidative stress (OS) in precipitating neurodegenerative diseases including sporadic Alzheimer’s disease (AD), requires further clarification. In addition to neuropathological hallmarks—extracellular neuritic amyloid-β (Aβ) plaques, neurofibrillary tangles (NFT) containing hyperphosphorylated tau and neuronal loss—chronic inflammation, as well as oxidative and excitotoxic damage, are present in the AD brain. The pathological sequelae and the interaction of these events during the course of AD need further investigation. The brain is particularly sensitive to OS, due to the richness of its peroxidation-sensitive fatty acids, coupled with its high oxygen demand. At the same time, the brain lack robust antioxidant systems. Among the multiple mechanisms and triggers by which OS can accumulate, inflammatory cytokines can sustain oxidative and nitrosative stress, leading eventually to cellular damage. Understanding the consequences of inflammation and OS may clarify the initial events underlying AD, including in interaction with genetic factors. Inflammatory cytokines are potential inducers of aberrant gene expression through transcription factors. Susceptibility disorders for AD, including obesity, type-2 diabetes, cardiovascular diseases and metabolic syndrome have been linked to increases in the proinflammatory cytokine, IL-18, which also regulates multiple AD related proteins. The association of IL-18 with AD and AD-linked medical conditions are reviewed in the article. Such data indicates that an active lifestyle, coupled to a healthy diet can ameliorate inflammation and reduce the risk of sporadic AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genomic responses in mouse models poorly mimic human inflammatory diseases
Seok, J., Warren, H. S., Cuenca, A. G., Mindrinos, M. N., Baker, H. V., Xu, W., Richards, D. R., McDonald-Smith, G. P., Gao, H., Hennessy, L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222878110 · Cited by 3,005
Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance
Calder, P. C. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.08.010 · Cited by 1,717
Microglia in neurodegenerative disease
Perry, V. H., Nicoll, J. A. R., & Holmes, C. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.17 · Cited by 1,543
Inflammation in neurodegenerative diseases
Amor, S., Puentes, F., Baker, D., & Van Der Valk, P. (2010) · Immunology · doi:10.1111/j.1365-2567.2009.03225.x · Cited by 1,355
Systemic inflammation and disease progression in Alzheimer disease
Holmes, C., Cunningham, C., Zotova, E., Woolford, J., Dean, C., Kerr, S., Culliford, D., & Perry, V. H. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b6bb95 · Cited by 1,139 · cited 1×
“Still, systemic inflammation can worsen symptoms in neurodegenerative diseases, including AD [17], and can also increase brain OS [18] as well as blood-brain barrier (BBB) permeability [19].”
BackgroundGuillemin, G. J., Smythe, G., Takikawa, O., & Brew, B. J. (2005) · Glia · doi:10.1002/glia.20090 · Cited by 497 · cited 1×
“The products of the KP can be excitotoxic, such as quinolinic acid, as well as diabetogenic, with such KP products proposed to contribute to AD neuropathology [43,44].”
BackgroundMorales, I., Guzmán-MartÃnez, L., Cerda-Troncoso, C., FarÃas, G. A., & Maccioni, R. B. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00112 · Cited by 490 · cited 1×
“Activated microglia release an array of inflammatory factors, including inflammatory cytokines and oxidative substances, as do reactive astrocytes, although generally to a lesser degree, versus microglia [24].”
BackgroundPeroxiredoxin 6: A Bifunctional Enzyme with Glutathione Peroxidase and Phospholipase A 2 Activities
Fisher, A. B. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3412 · Cited by 410 · cited 1×
“As well as reducing H2O2, PRX6 can also reduce short chain organic fatty acids and phospholipid hydroperoxides, indicating the importance of PRX6 in phospholipid turnover [51].”
Lipid rafts, cholesterol, and the brain
Korade, Z., & Kenworthy, A. K. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.02.019 · Cited by 342
Improving influence of insulin on cognitive functions in humans
Kern, W., Peters, A., Fruehwald-Schultes, B., Deininger, E., Born, J., & Fehm, H. L. (2001) · Neuroendocrinology · doi:10.1159/000054694 · Cited by 308
Hamer, M., Sabia, S., Batty, G. D., Shipley, M. J., Tabák, A. G., Singh-Manoux, A., & Kivimaki, M. (2012) · Circulation · doi:10.1161/circulationaha.112.103879 · Cited by 280
Weight loss reduces interleukin-18 levels in obese women
Esposito, K., Pontillo, A., Ciotola, M., Di Palo, C., Grella, E., Nicoletti, G., & Giugliano, D. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.8.8781 · Cited by 254 · cited 1×
“IL-18 levels are elevated in AD brains [23], as well as in diseases that increase AD risk, including T2DM [32], obesity [33], and ischemic heart disease [34].”
BackgroundExpression of interleukin-18 is increased in the brains of Alzheimer’s disease patients
Ojala, J., Alafuzoff, I., Herukka, S.-K., van Groen, T., Tanila, H., & Pirttilä, T. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.06.006 · Cited by 235
Self-citationEffect of lifestyle activities on alzheimer disease biomarkers and cognition
Vemuri, P., Lesnick, T. G., Przybelski, S. A., Knopman, D. S., Roberts, R. O., Lowe, V. J., Kantarci, K., Senjem, M. L., Gunter, J. L., Boeve, B. F., et al. (2012) · Annals of Neurology · doi:10.1002/ana.23665 · Cited by 193
Docosahexaenoic and eicosapentaenoic acids segregate differently between raft and nonraft domains
Williams, J. A., Batten, S. E., Harris, M., Rockett, B. D., Shaikh, S. R., Stillwell, W., & Wassall, S. R. (2012) · Biophysical Journal · doi:10.1016/j.bpj.2012.06.016 · Cited by 168
Reed, T. T., Pierce Jr., W. M., Turner, D. M., Markesbery, W. R., & Allan Butterfield, D. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00478.x · Cited by 135
Nutrition and AGE‐ing: Focusing on Alzheimer’s Disease
Abate, G., Marziano, M., Rungratanawanich, W., Memo, M., & Uberti, D. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/7039816 · Cited by 103
Ojala, J. O., Sutinen, E. M., Salminen, A., & Pirttilä, T. (2008) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2008.09.012 · Cited by 102 · cited 9×
“Abbreviations Aβ, Amyloid-β; AD, Alzheimer’s disease; ADL, activities of daily living; ADMA, N(G),N(G)-dimethyl-Larginine; AGE, advanced glycation end product; APP, Amyloid-β precursor protein; AMPK, adenosine monophosphate (AMP)-activated protein kinase; ASC, apoptosis-associated speck-like protein containing a CARD…”
BackgroundInfluentialSelf-citationTrøseid, M., Arnesen, H., Hjerkinn, E. M., & Seljeflot, I. (2009) · Metabolism · doi:10.1016/j.metabol.2009.04.031 · Cited by 73 · cited 3×
“Healthy diet containing omega-3 fatty acids and antioxidants can also be effective in reducing IL-18 levels [154,155].”
BackgroundCampos-Peña, V., Toral-Rios, D., Becerril-Pérez, F., Sánchez-Torres, C., Delgado-Namorado, Y., Torres-Ossorio, E., Franco-Bocanegra, D., & Carvajal, K. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6768 · Cited by 58
Nitric oxide‐mediated regulation of ‐amyloid clearance via alterations of MMP‐9/TIMP‐1
Ridnour, L. A., Dhanapal, S., Hoos, M., Wilson, J., Lee, J., Cheng, R. Y. S., Brueggemann, E. E., Hines, H. B., Wilcock, D. M., Vitek, M. P., et al. (2012) · Journal of Neurochemistry · doi:10.1111/jnc.12028 · Cited by 54
Sutinen, E. M., Korolainen, M. A., Häyrinen, J., Alafuzoff, I., Petratos, S., Salminen, A., Soininen, H., Pirttilä, T., & Ojala, J. O. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00214 · Cited by 34 · cited 10×
“Protein levels of dimethylarginine dimethylaminohydrolase 2 (DDAH2) can also be regulated by IL-18 [40].”
BackgroundSelf-citation
Cited by
Role of Blood-Brain Barrier in Alzheimer’s Disease
Cai, Z., Qiao, P.-F., Wan, C.-Q., Cai, M., Zhou, N.-K., & Li, Q. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180098 · Cited by 370
“Third, both neuroinflamma-tion and oxidative stress induced by BBB damage can accelerate the development of tau hyperphosphorylation and NFT formation [127, 128].”
The biological pathways of Alzheimer disease: a review
Calabrò, M., Department of Biomedical and Dental Sciences and Morphofunctional Imaging, U. O. M., Rinaldi, C., Santoro, G., & Crisafulli, C. (2021) · AIMS Neuroscience · doi:10.3934/neuroscience.2021005 · Cited by 265
Reich, N., & Hölscher, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.970925 · Cited by 248
Role of p38/MAPKs in Alzheimer's Disease: Implications for Amyloid Beta Toxicity Targeted Therapy
Kheiri, G., Dolatshahi, M., Rahmani, F., & Rezaei, N. (2018) · Reviews in the Neurosciences · doi:10.1515/revneuro-2018-0008 · Cited by 211
Ikram, M., Saeed, K., Khan, A., Muhammad, T., Khan, M., Jo, M., Rehman, S., & Kim, M. (2019) · Nutrients · doi:10.3390/nu11051082 · Cited by 97
“Moreover, it has been shown that the consumption of alcohol leads to the generation of free radicals and to the chain reaction of lipid peroxidation that causes damage to the brain and other vital organs [9,10].”
Retracted
Metadata
- Authors
- Ojala, J., & Sutinen, E.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2017-05-21
- Volume
- 6
- Issue
- 5
- Pages
- 55
- ISSN
- 2077-0383 (ISSN-L)
- OpenAlex
- W2614736523
- Cited by
- 64
- References
- 22
- FWCI
- 3.78
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.